Skip to Content
Merck

HIV-1 resists MxB inhibition of viral Rev protein.

Emerging microbes & infections (2020-09-03)
Zhen Wang, Keli Chai, Qian Liu, Dong-Rong Yi, Qinghua Pan, Yu Huang, Juan Tan, Wentao Qiao, Fei Guo, Shan Cen, Chen Liang
ABSTRACT

The interferon-inducible myxovirus resistance B (MxB) protein has been reported to inhibit HIV-1 and herpesviruses by blocking the nuclear import of viral DNA. Here, we report a new antiviral mechanism in which MxB restricts the nuclear import of HIV-1 regulatory protein Rev, and as a result, diminishes Rev-dependent expression of HIV-1 Gag protein. Specifically, MxB disrupts the interaction of Rev with the nuclear transport receptor, transportin 1 (TNPO1). Supporting this, the TNPO1-independent Rev variants become less restricted by MxB. In addition, HIV-1 can overcome this inhibition by MxB through increasing the expression of multiply spliced viral RNA and hence Rev protein. Therefore, MxB exerts its anti-HIV-1 function through interfering with the nuclear import of both viral DNA and viral Rev protein.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Leptomycin B solution from Streptomyces sp., ≥95% (HPLC), Supplied in methanol: water (7:3)
Sigma-Aldrich
Thymidine 5′-triphosphate sodium salt, ≥96%
Sigma-Aldrich
MISSION® esiRNA, targeting human TNPO1
Sigma-Aldrich
Anti-HIV-1 P24 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal ANTI-FLAG® M2 antibody produced in mouse, 1 mg/mL, clone M2, affinity isolated antibody, buffered aqueous solution (50% glycerol, 10 mM sodium phosphate, and 150 mM NaCl, pH 7.4)
Sigma-Aldrich
MISSION® esiRNA, targeting human KPNB1
Sigma-Aldrich
Duolink® In Situ Red Starter Kit Mouse/Rabbit